drugset / Trial / NCT06789861

A First in Human Study of TT5 in Single and Multiple Ascending Doses in Healthy Volunteers and Surgical Patients

NCT06789861 ↗

Phase 1 Recruiting 94 enrolled Tafalgie Therapeutics
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is a First in Human, three-parts, double-blind, randomized, placebo-controlled, single and multiple ascending dose study. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TT5 at different doses in healthy and surgical participants.

Timeline

Start
2025-05-23
Primary completion
2026-10-01
Completion
2026-11-10

Drugs

EvaluationDrugModalityDoseRoute
Subject TT5 Unknown — Intravenous

Indications

No indication recorded.